Biocorp Production designs, develops, and manufactures medical devices in France. The company provides Inspair, a smart cap to monitor inhalers and assesses the usage of the device; Mallya, a smart cap for pen injectors that captures injection data; Datapen, a motor driven pen injector; and Injay which collects essential information, such as injection completed, time and date, type of drug, batch number, and expiration date. It also offers pharmaceutical devices, such as NEWGUARD, a safety device compatible with various sizes of prefilled syringes; BIOPASS, a reconstitution system with a needle; Sween, a device that provides real assistance in the administration of medication and closure systems. The company was incorporated in 2004 and is headquartered in Issoire, France. As of August 4, 2023, Biocorp Production operates as a subsidiary of Novo Nordisk A/S.
Research context
Biocorp Production appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Biocorp Production is currently in a long term downtrend where the price is trading 9.4% below its 200 day moving average.
From a valuation standpoint, the stock is 93.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.7.
Based on the above factors, Biocorp Production gets an overall score of 1/5.